# HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.

> **NCT00412022** · PHASE3 · UNKNOWN · sponsor: **National Cancer Institute, Naples** · enrollment: 1294 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** tamoxifen
- **DRUG:** triptorelin
- **DRUG:** letrozole
- **DRUG:** zoledronic acid

## Key facts

- **NCT ID:** NCT00412022
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-03
- **Primary completion:** 2024-11
- **Final completion:** 2024-11
- **Target enrollment:** 1294 (ACTUAL)
- **Last updated:** 2023-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00412022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00412022, "HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00412022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*